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Amyloidosis is a group of rare diseases in which
a specific protein is deposited as aggregated interstitial
fibrils that can compromise organ function and lead to
death [1]. In the case of immunoglobulin light chain
amyloidosis (AL), the specific protein is the light chain
of the monoclonal gammopathy of a plasma cell dys-
crasia. This is a rare disorder occurring at an incidence
of 9 per million per year [2], which is about 1/5 as com-
mon as multiple myeloma (MM).
The mechanism by which AL amyloid fibrils are
formed is not well understood. It is postulated that
the immunoglobulins are secreted, most commonly
with an excess of unchaparoned free light chains
[3,4]. These light chains are then somehow proteo-
lyzed and/or processed into oligomers and finally non-
branching fibrils (8-10 nm) that are deposited in the
microcirculation. In the case of renal involvement, it
has been postulated that some of this process occurs
in mesangial cells [5].
PRESENTING SYMPTOMS AND SIGNS
The spectrum of presentations is diverse, because
this is a systemic disease that can affect almost any
organ system outside of the central nervous system.
A high index of suspicion is required for prompt diag-
nosis and avoidance of unnecessary morbidity and
mortality. The 2 most frequently involved organs sys-
tems are the kidney and the heart, followed by the liver
and nervous system [2,6,7]. Figure 1A demonstrates
the dominant organ presentation during a 10-year
period at 2 amyloid treatment centers. Pulmonary,
lymph node, and muscular involvement is also possi-
ble, but is less common andmore difficult to document
in the case of pulmonary and muscle involvement.6Classic symptoms and signs such as dramatic peri-
orbital purpura, macroglossia, and the shoulder pad
sign are pathognomonic, but each occurs in fewer
than 10% to 15% of patients, making them inadequate
to make a timely diagnosis of the syndrome for most
patients.
One of the most common presenting symptoms is
peripheral edema (Figure 1B), which occurs in just
over 40% of patients. The most common cause for
edema is hypoalbuminemia because of nephrotic syn-
drome, but it can also be because of heart failure or
obstructive liver disease.
Fatigue is present in 35% to 45% of patients,
wherease dyspnea is present in approximately 20%.
These symptoms often represent cardiac involvement,
which may go undiagnosed because of unrecognized
subtle diastolic dysfunction and mild to moderate left
ventricular hypertrophy, because of the preservation
of left ventricular ejection fraction.
Orthostatic hypotension is another common find-
ing. This, too, can be because of 1 or more of the fol-
lowing: volume contraction from overzealous diuretic
therapy to treat nephrotic syndrome or heart failure,
autonomic nervous system involvement, or low cardiac
output.
Ten percent to 35% of patients may report pares-
thesias. The paresthesias in the hands are most com-
mon because of median nerve entrapment by buildup
of amyloid at the carpal ligament. The paresthesias
in the feet tend to be dysesthetic in quality and because
of a small fiber peripheral neuropathy.
Symptomatic gastrointestinal involvement is rare,
but biopsies are positive in the majority of patients
sampled. The reason for this disparity relates to the
principle that amyloid affects microvessels, and may
therefore be found in virtually any biopsy sample
Amyloidosis 7with a vessel. With the exception of claudication-type
symptoms, as a rule, an organ becomes symptomatic
when the amyloid has spread beyond the vessels into
the interstitium.
Bleeding may also be present because of an assort-
ment of coagulation abnormalities, most commonly
factor X deficiency, but also because of capillary fragil-
ity, which results in purpura occurring most notably
around the eyes and neck.
DIAGNOSIS
The presence of a monoclonal protein in the serum
and/or urine and any of the above presenting features
should alert the treating physician to the possibility
that a patient has AL amyloidosis. The diagnosis is
made by biopsying either an affected organ or a more
readily available vascular tissue like fat, bone marrow,
or gastrointestinal mucosa. If the tissue stains with
Congo Red, and there is green birefringence, the pa-
tient can be labeled as having amyloidosis. It is impor-
tant to note that not all amyloid is AL amyloid and not
all AL is systemic. Although AL amyloidosis is the
most common type, hereditary, senile, and secondary
forms exist, and should not be confused with AL amy-
loidosis because of the different therapies indicated. In
addition, a minority of patients may have localized am-
yloidosis, an entity in which the plasma cells producing
the amyloidogenic protein are at the site of the amyloid
rather than at the bone marrow. The most common
sites for localized amyloidosis are the genitourinary
tract, the respiratory tract, and the lymph nodes.
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Figure 1. Presenting amyloid syndromes and symptoms at 2 large
amyloid centers. (A) Dominant organ involvement at presentation.
(B) Symptoms at presentation. (Based on data from Palladini G,
et al. Amyloid. 2005;12:120-126.)Once a diagnosis of amyloidosis is made, all efforts
should be made to type the amyloid itself either by
immunohistochemistry or direct sequencing of the
amyloid itself.Merely documenting amonoclonal pro-
tein or monoclonal plasma cells is not sufficient [8,9].
DNA-based screening for the most common heredi-
tary forms of amyloid may also be a helpful means of
exclusion.
PROGNOSIS
Once a diagnosis of AL amyloidosis is made, it is
important to define prognosis. The extent of cardiac
involvement is by far the most important prognostic
parameter in these patients. As early as the 1970s, it
was shown that patients presenting with cardiogenic
syncope or CHF hadmedian survivals of 4 to 6months
[10].
The number of symptomatic organs was also iden-
tified as a prognostic factor for patients, especially
those undergoing high-dose chemotherapywith hema-
topoietic stem cell transplantation (HSCT) [11]. Prob-
lems arose with counting numbers of organs because
there was no standardized definition of organ involve-
ment until recently [12]. Although implementation of
standardized definitions of involved organs is a major
improvement, these definitions do not provide infor-
mation about the degree of organ involvement. The
survival of someonewith advanced cardiac involvement
is a fraction of that of an individual with early involve-
ment (Figure 2). Fortunately, the Pavia group and the
Mayo group have identified that cardiac biomarkers
are powerful predictors of survival both at presentation
[13-15] and during treatment with cytotoxic chemo-
therapy [16]. The advantage of the cardiac biomarkers
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Figure 2. Predicting outcome postautologous peripheral blood stem
cell transplant based on cardiac biomarker staging system. Stage 1,
both biomarkers below cutoff; stage 2, 1 of the 2 biomarkers below
cutoff; and stage 3, both biomarkers above cutoffs. Cutoffs troponin
T\0.035 mg/L and NT-proBNP\332 ng/L (39 pmol/L). Results
updated from original publication published in Blood.
2004;104:1881-1887. Median follow-up of surviving patients is
35.5 months.
8 A. Dispenzieri et al.is that they are more readily available and reproducible
than echocardiography. As one uses these assays, one
must be cognizant that there are 2 troponin measure-
ments most commonly in use: the troponin T and the
troponin I, 2 brain natriuretic peptide (BNP) assays,
the BNP and the N-terminal BNP. The prognostic
usefulness holds true regardless of the assay, but the
critical thresholds will vary. For example, a conversion
factor between BNP and NT-proBNP is: log BNP 5
0.28 1 0.66 ) log NT-ProBNP.
Other important prognosticators include baseline
serum immunoglobulin-free light chain (FLC) [17],
beta-2 microglobulin [18], and plasma cell labeling
index [19].
NONTRANSPLANT THERAPIES FOR AL AMYLOIDOSIS
The treatment of the systemic amyloidoses varies
greatly according to the type of amyloidosis; therefore,
accurate diagnosis is of vital importance. At present,
the best approach to treating amyloidosis remains in
the realm of restricting the amount of protein substrate
necessary for amyloid fibril formation. For AL amy-
loidosis, the current therapeutic approach is based on
the observation that organ function can be restored if
the synthesis of the amyloidogenic precursor is shut
down. The aim of therapy is to rapidly reduce the sup-
ply of the amyloidogenic monoclonal light chain by
suppressing the underlying plasma cell clone, while
using supportive measures to sustain the function of
the organs involved [20]. A consensus panel from the
International Society for Amyloidosis established the
criteria for hematologic and organ response [12]. It
has been demonstrated that achievement of a hemato-
logic response was an important predictor of pro-
longed survival after HSCT for patients with AL.
The degree of response is relevant because patients
who achieved a complete response survived longer
than those who achieved a partial response, thus indi-
cating that hematologic response may be used as an
endpoint in trials assessing AL amyloidosis therapies
[21-23]. The recent, unpublished data of Merlini et
al indicate that the serial concurrent quantification of
the FLC andNT-proBNP in patients with cardiac am-
yloidosis allows titration of the treatment against the
clonal plasma cells according to the organ response,
thus optimizing the toxicity-benefit ratio and allowing
a prompt change of therapy in the case of an inade-
quate response.
Important progress has been achieved since the
mid-1990s when a melphalan and prednisone regimen
was considered standard therapy [24]. This combina-
tion induced slow responses, which were rarely com-
plete, in about 25% to 30% of patients. The advent
of high-dose melphalan followed by rescue with autol-
ogous HSCT dramatically changed the perspective for
AL amyloidosis care, demonstrating that completeresponse can be achieved in a substantial proportion
of eligible patients which translated into organ re-
sponse and significant survival extension [25].
Although HSCT represents a breakthrough in the
care of AL amyloidosis, its toxicity has limited its
benefit to a minority of patients. Therefore, the search
for less toxic and rapidly acting regimens continued. A
multicenter trial showed that dexamethasone alone
achieves a 53% hematologic response rate after a me-
dian time of 3.4 months, with 24% complete remis-
sions and a treatment-related mortality (TRM) of
7% [26]. The addition of oral melphalan to dexameth-
asone (MDex) induced a hematologic response in 67%
(CR 33%) of AL patients ineligible for HSCT because
of advanced disease, in a median time of 4.5 months,
with a low TRM of 4% [27]. The extended follow-
up of the patients treated with MDex shows that the
responses were durable with median progression-free
survival (PFS) of 3.8 years and median overall survival
(OS) of 5.1 years [28].
Although thalidomide is poorly tolerated in AL pa-
tients [29,30], its association with dexamethasone as
second-line treatment induces a hematologic response
in 48% of patients with 19% CR [31]. A risk-adapted
oral regimen of cyclophosphamide, thalidomide, and
dexamethasone (CTD) in patients with AL amyloid-
osis produced hematologic response in 74% of pa-
tients including complete responses in 21% with
a TRM of 4% [32]. This regimen has the advantage
of preserving HSCs for possible subsequent autolo-
gous HSCT, but the actual toxicity of the regimen is
not well understood because the regimen was not
tested as a formal clinical trial. New drugs have been
recently adopted from the therapeutic armamentarium
for MM for the treatment of AL amyloidosis. The
Mayo Clinic and the Boston University groups
reported that the thalidomide analog, lenalidomide,
particularly when used in combination with dexameth-
asone, in patients with AL amyloidosis, many of whom
were previously treated, induced approximately 50%
hematologic response with 22% complete responses.
Fatigue and myelosuppression were the most common
treatment-related adverse events, whereas thrombo-
embolic complications were the most serious [33,34].
These findings indicate that the combination of lenali-
domide and dexamethasone represents a valid treat-
ment option. The proteasome inhibitor, bortezomib,
is undergoing an international phase I-II dose-escalat-
ing trial in previously treated patients, and preliminary
results indicate that this drug can be rapidly effective in
a significant proportion of patients with manageable
toxicity [35-37].
The goal of chemotherapy is a rapid and effective
suppression of the synthesis of the amyloidogenic light
chain to induce a functional improvement of the organ
involved with minimal toxicity. The only randomized
trial comparing modern therapies is the French
Amyloidosis 9Multicentric Trial on HSCT and MDex [38]. The
trial showed that HSCT was not superior to MDex
in a multicenter setting, and was associated with low-
er survival when patients were treated in centers
without great experience (see next section for further
discussion).
Optimal therapy for AL amyloidosis remains
undetermined because of the lack of large compara-
tive randomized clinical trials to support the use of
1 agent over another. It is likely that in the near
future, early diagnosis and combination therapy
with alkylating agents associated with dexametha-
sone, thalidomide, and the new drugs lenalidomide
and bortezomib, would lead to an extended and bet-
ter life for all AL patients. Supportive therapy is of
paramount importance for gaining time, whereas spe-
cific therapy takes effect (reviewed in reference [39]).
Heart [40] or kidney transplantation [41] followed by
autologous HSCT has been successfully applied in
selected patients.
HIGH-DOSE CHEMOTHERAPY WITH PERIPHERAL BLOOD
STEM CELL TRANSPLANT FOR AL AMYLOIDOSIS
High-dose chemotherapy with HSCT for patients
with AL amyloidosis began to come into favor in the
mid-1990s [11,21,23,42-47]. The very first reports
were associated with high TRM [43]. However, with
risk-based melphalan dose reduction, more patients
became eligible for the procedure. For many it was
considered the treatment of choice for patients with
AL amyloidosis because amyloidosis centers perform-
ing HSCT and delivering 200 mg/m2 of melphalan as
conditioning could boost median survivals approach-
ing 8 years [31]. Sicker patients who were treated
with attenuated doses of melphalan conditioning
(100 to 140 mg/m2) could also be brought through
the procedure with a TRM of about 14%, but fared
less well with regard to hematologic and organ re-
sponse rates as well as OS [21,22].
Questions arose regarding selection bias being
responsible for superior outcomes [48], but later,
a case-controlled study demonstrated improved sur-
vival in patients receiving high-dose melphalan with
HSCT [49]. As mentioned, Palladini et al [27], how-
ever, demonstrated that patients too sick for transplant
could not only tolerate MDex, but could achieve
remarkably high hematologic and organ response
rates. Lachmann et al [3] had previously shown that
2 to 6 cycles of low dose intravenous melphalan (25
mg/m2) was also associated with an immunoglobulin
free light response rate of approximately 50%.
These findings prompted the Myelome Autogreffe
(MAG) and the Intergroupe Francophone du
Myelome (IFM) Intergroup to perform a risk adapted
multicenter randomized controlled trial of 100 pa-
tients, half receiving melphalan and dexamethasone(MDex) and the other half receiving high-dose mel-
phalan with autologous HSCT. Over a 5-year period,
from 2000 to 2005, 100 patients were enrolled at 29
centers [38]. Among the MDex group, 1 patient died
before starting treatment and another died within 3
days of starting treatment, with 96% of patients receiv-
ing at least 1 cycle of therapy. Eighty-six percent of pa-
tients received 3 or more cycles of therapy with the
median number of cycles of 12. In contrast, among
the 50 patients randomized to high-dose melphalan,
only 37 (74%) received high-dose melphalan. Reasons
included refusal (n 5 1), death before stem cell mobi-
lization (n 5 1), insufficient stem cell collection
(n 5 2), death during stem cell mobilization (n 5 4),
and sudden death after stem cell collection but before
conditioning (n 5 5). Of the 37 patients receiving
high-dose melphalan, 9 died within 100 days of stem
cell infusion resulting in a postrandomization early
mortality rate of 38%. Conditioning doses of melpha-
lan used were 140 mg/m2 and 200 mg/m2 in 10 and 27
patients, respectively.
The authors addressed hematologic response in 38
MDex and 27 HSCT patients at 100 days, and found
that rates were comparable with just over 2/3 of surviv-
ing patients achieving hematologic responses. A higher
percentage of responses in the HSCT group were
complete responses. On an intention-to-treat basis,
however, overall hematologic responses for MDex
and HSCT were 52% and 36%, respectively. More-
over, organ responses were seen in 17 and 13 patients,
respectively. With 36 months of follow-up for surviv-
ing patients, the median survival rates were 57 and 22
months, respectively. When a landmark analysis was
performed at 6 months, the OS rates between the 2
arms were identical.
So, what conclusions can be drawn from this
important, but small, randomized trial? The first is
that it confirms the results from Merlini’s group that
MDex is a highly active treatment for AL amyloidosis
patients, including those with high-risk disease [27]. It
serves as yet another study that highlights the strong
association between hematologic response, organ
response, and survival. It also confirms that HSCT is
associated with exceptionally high TRM when per-
formed outside of transplant centers with amyloidosis
expertise [47,50]. A major shortcoming of this study,
however, is the lack of modern cardiac biomarkers to
assure balance between treatment arms. Given the
small sample size and the known heterogeneity of the
disease, impeccable matching of the most relevant
prognosticmarkers is essential to guarantee that differ-
ences and/or similarities between treatment arms are
related to treatment effect rather than patient sam-
pling. The fact that half as many patients died before
completing 3 cycles of MDex compared to those dying
prior to receiving high-dose melphalan would suggest
that such an imbalance may have existed.
10 A. Dispenzieri et al.SUMMARY
AL amyloidosis is a rare disease in which immuno-
globulin light chains are deposited as aggregated inter-
stitial fibrils that can compromise organ function and
lead to death. The risks that patients with amyloidosis
face include late diagnosis, misdiagnosis of amyloid
type, untimely and ineffective therapy, and toxicities
of therapy. The goals of treatment are (1) reduction
or elimination of the amyloid-forming protein, usually
a free immunoglobulin light chain measured by the
serum-free light chain assay; (2) support of the patient
pending hematologic response and improvement; and
(3) stabilization of organ function. Whenever possible,
patients should be treated on clinical trials.
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